Armata Pharmaceuticals Highlights AP-SA02 Data at ISSSI 2026
Marina del Rey, California, U.S., September 21, 2026 Armata Pharmaceuticals announced that new data evaluating AP-SA02, its investigational bacteriophage...
Staphylococcus aureus
Advertisement
Armata’s AP-SA02 Receives FDA Breakthrough Designation
Los Angeles, California, U.S., September 14, 2026 Armata Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has...
Turn Therapeutics Reports GX-03 Skin Inflammation Research
Westlake Village, California, August 20, 2026 Turn Therapeutics announced new peer-reviewed research providing in-vivo evidence that GX-03 selectively reduces...
Armata Advances AP-SA02 Toward Phase III Bacteremia Trial
LOS ANGELES, July 20, 2026 Armata Pharmaceuticals, Inc. has announced significant clinical, regulatory, manufacturing, and operational progress supporting the...
Armata Secures $2.5M DoD Funding for AP-SA02
LOS ANGELES, Calif. | June 23, 2026 Armata Pharmaceuticals has received an additional $2.5 million in non-dilutive funding from...
Advertisements
Boehringer Introduces LENZELTA Vaccine for Mastitis Control
INGELHEIM, GERMANY, April 13, 2026 Boehringer Ingelheim has introduced LENZELTA®, a new veterinary vaccine designed to prevent mastitis in...
Armata Announces Phase 2a Success for S. aureus Phage Therapy
Los Angeles, CA – October 22, 2025 — Armata Pharmaceuticals, Inc., a biotechnology company advancing bacteriophage-based therapeutics, announced positive...
Advertisement
